key: cord-0280603-k2qertx2
authors: Park, Young-Jun; Pinto, Dora; Walls, Alexandra C.; Liu, Zhuoming; Marco, Anna De; Benigni, Fabio; Zatta, Fabrizia; Silacci-Fregni, Chiara; Bassi, Jessica; Sprouse, Kaitlin R.; Addetia, Amin; Bowen, John E.; Stewart, Cameron; Giurdanella, Martina; Saliba, Christian; Guarino, Barbara; Schmid, Michael A.; Franko, Nicholas; Logue, Jennifer; Dang, Ha V.; Hauser, Kevin; di Iulio, Julia; Rivera, William; Schnell, Gretja; Lempp, Florian A.; Janer, Javier; Abdelnabi, Rana; Maes, Piet; Ferrari, Paolo; Ceschi, Alessandro; Giannini, Olivier; Dias de Melo, Guilherme; Kergoat, Lauriane; Bourhy, Hervé; Neyts, Johan; Soriaga, Leah; Purcell, Lisa A.; Snell, Gyorgy; Whelan, Sean P.J.; Lanzavecchia, Antonio; Virgin, Herbert W.; Piccoli, Luca; Chu, Helen; Pizzuto, Matteo Samuele; Corti, Davide; Veesler, David
title: Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
date: 2022-05-09
journal: bioRxiv
DOI: 10.1101/2022.05.08.491108
sha: 11954057e153d3518092d3a931b0c8e2caf2786e
doc_id: 280603
cord_uid: k2qertx2

SARS-CoV-2 Omicron sublineages carry distinct spike mutations and represent an antigenic shift resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters result in potent plasma neutralizing activity against Omicron BA.1 and BA.2 and that breakthrough infections, but not vaccination-only, induce neutralizing activity in the nasal mucosa. Consistent with immunological imprinting, most antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases cross-react with the Wuhan-Hu-1, BA.1 and BA.2 receptor-binding domains whereas Omicron primary infections elicit B cells of narrow specificity. While most clinical antibodies have reduced neutralization of Omicron, we identified an ultrapotent pan-variant antibody, that is unaffected by any Omicron lineage spike mutations and is a strong candidate for clinical development.

. Evaluation of plasma, memory and mucosal antibody responses upon Omicron breakthrough infections in humans. A, Pairwise neutralizing activity (half-maximum inhibitory dose; ID50) against Wu-G614, Delta, BA.1, BA.2 and SARS-CoV S VSV pseudoviruses using plasma from subjects who were infected and vaccinated, vaccinated and experienced breakthrough infection, or vaccinated-only individuals. Vero E6-TMPRSS2 cells were used as target cells (33) . Data are the geometric mean of an n = 2 technical replicate and have been performed in at least 2 biologically independent experiments. GMTs are shown with a color-matched bar (and reported in Table S1 ) with fold change compared to Wu-G614 indicated above it. Demographics of enrolled

The recently described ACE2-mimicking S2K146 mAb (35) that retained unaltered activity against BA.1 compared to G614 (3), had a mildly reduced neutralizing activity against BA.2 and BA.3 (3.3-fold and 3.1-fold, respectively). However, S2K146 displayed a marked reduction in neutralizing activity against BA.4 and BA.5 (427-fold and 285-fold drops in IC50s compared to Wu-G614), likely due to the F486V mutation.

Sotrovimab, a site IV mAb with broad sarbecovirus (clade Ia and Ib) cross-neutralizing activity (36) , had a more pronounced (16-fold and 7.3-fold) decrease in potency against BA.2 and BA.3, respectively, compared to BA.1 (2.7-fold), although no additional BA.2 or BA.3 residue mutations map to the epitope (36) (37) (38) . This reduced neutralization might result from the BA.2 and BA.3 S371F substitution which introduces a bulky residue that could reposition the nearby N343 glycan, which is part of the sotrovimab epitope, as supported by molecular dynamics simulations (39) (Fig. S9A-E) . Although we could not test the effect of the S371F substitution alone in the Wu-G614 S background (due to poor VSV pseudovirus infectivity), the S371F, S373P and S375F triple mutant (as found in BA.2, BA.3, BA.4, BA.5 and BA.2.12.1) reduced sotrovimab-mediated neutralization by 3.4-fold relative to Wuhan-Hu-1 (D614). Moreover, the S371L, S373P and S375F triple mutant (as found in BA.1) did not alter sotrovimab activity ( Fig. S9F and Table S4) , lending further support to the role of F371 in repositioning the N343 glycan and explaining the reduced potency against BA.2 and BA.3. S2X259, a site IIa mAb that broadly reacts with the RBD of multiple sarbecoviruses (31) retained activity against BA.1 (3). However, S2X259 neutralization was decreased by more than tenfold against BA.2, BA.3, BA.4, BA.5 and BA.2.12.1, likely due to the detrimental effect of the R408S mutation (31) . S2H97 is a site V mAb that experienced a 4.7-fold to 10-fold decrease in neutralization potency against Omicron sublineages compared to Wu-G614 despite the absence of mutations present in the epitope or otherwise found to affect binding by DMS, perhaps reflecting differential accessibility to its cryptic epitope in the context of the S trimer (25) .

The S2X324 mAb stood out in our panel as its neutralization potency was unaffected by BA.1, BA.2, BA.3, BA.4, BA.5 and BA.2.12.1 S mutations ( Fig. 2A) . S2X324 bound to BA.1 and BA.2 RBDs with high affinity (Fig. S10A and Table S5 ) and cross-reacted with and neutralized all SARS-CoV-2 variants tested with IC50s below 10 ng/ml (Fig. 2B) . S2X324 cross-reacted with the sarbecovirus clade 1b Pangolin-GD RBD, but did not recognize more divergent sarbecovirus RBDs (Fig. 2C) including SARS-CoV, distinguishing this mAb from previously described broadly neutralizing sarbecovirus mAbs such as S2X259 (31) , S2K146 (35) , S2H97 (25) and sotrovimab (36) . Epitope binning experiments showed that S2X324 did not compete with the site I mAb S2K146 or site II mAbs S304 and S2X259 but did compete with the site I mAb S2H14 and the site IV mAb sotrovimab (Fig. S10B) . S2X324 inhibited binding of the SARS-CoV-2 RBD to human ACE2 in a concentration-dependent manner, as measured by competition ELISA (Fig. 2D) and induced premature shedding of the S1 subunit (Fig. 2E) . This suggests that blockage of ACE2 binding as well as possible premature S1 shedding (40) may participate in S2X324-mediated inhibition of SARS-CoV-2. determined. (B) Neutralization of SARS-CoV-2 variants mediated by broadly neutralizing sarbecovirus mAbs. Each symbol represents the GMT of at least two independent experiments. (C) Cross-reactivity of S2X324 with sarbecovirus clades 1a and 1b RBDs analyzed by ELISA.

(D) Preincubation of serial dilutions of S2X324 or S2E12 with the SARS-CoV-2 RBD prevents binding to the immobilized human ACE2 ectodomain in ELISA. Error bars indicate standard deviation between replicates. (E) S2X324-mediated S1-shedding from cell surface-expressed SARS-CoV-2 S as determined by flow cytometry. S2E12 and S2X259 were used as positive controls whereas S2M11 and S309 were used as negative controls.

To understand the pan-variant S2X324 inhibitory activity, we determined a cryo-electron microscopy structure of the Omicron BA.1 S ectodomain trimer bound to the S2X324 Fab fragment at 3.1 Å resolution (Fig. 3A, Fig S12 and Table S6 ). In our structure, the Omicron S trimer has two open RBDs and one closed RBD with three bound Fabs. We used focused classification and local refinement of the closed RBD-S2X324 Fab complex to obtain a 3.3 Å structure revealing the molecular details of the binding interface.

S2X324 recognizes an RBD epitope partially overlapping with antigenic sites Ia/Ib and IV ( Fig. 3A-B) , explaining the observed competition with S2H14 (11) and S309 (36) mAbs. S2X324 utilizes all six complementary-determining loops to recognize RBD residues N439, K440, L441, S443, K444, V445, S446, G447, N450, R498, P499, T500, Y501, G502 and Q506 (Fig. 3C) . In line with the competition assay (Fig. 2D) , S2X324 overlaps with the ACE2-interaction site on the RBD and would sterically hinder receptor engagement (Fig. 3D) .

The structure explains how this mAb accommodates residues that are mutated in Omicron lineages relative to Wuhan-Hu-1: N440K (BA. (Fig. S10A) , might be due to G446S as although the mutation is clearly accommodated, at least 1 out of 3 favored rotamers for S446 would clash with the Fab. The Y501 backbone forms van der Waals interactions with the VL N32 side chain which are independent of the RBD residue identity at this position (explaining retention of neutralization of all Y501-containing variants). S2X324 and LY-CoV1404 share 87% and 91% amino acid sequence identity in their heavy and light chains, respectively, likely explaining their similar binding mode (41) and pan-variant neutralizing activity, including accommodation of mutations at position 452 (as found in BA.4 and BA.5), which are outside the epitope (Fig. S13) . 

To explore potential mutations that could promote escape from S2X324-mediated neutralization, we passaged a replication-competent VSV chimera harboring either SARS-CoV-2 S Wu-G614 (43) or Omicron BA.1 S in the presence of S2X324. Residue substitutions at three distinct sites emerged ( Fig. 3C and Fig. S14A-B) : (i) K444N/T (Wu-G614 and BA.1 background) and K444E/M (BA.1 background), that would abrogate the salt bridges formed between the K444 side chain and the heavy chain D56 and D58 side chains; (ii) V445D (Wu-G614 background) and V445A/F (BA.1 background), which would disrupt Van der Waals contacts with S2X324; and (iii) P499R (Wu-G614 background) and P499S/H (BA.1 background) that might alter the local RBD backbone conformation and/or sterically hinder mAb binding (Tables S7-S9) . Furthermore, three additional mutations were retrieved in the BA.1 S background only: S446I, G447S, and N448K, which reside at the interface between the heavy and light chains. The K444N, V445D and P499R S chimeras were outcompeted by the Wuhan-Hu-1/D614G S chimera after four rounds of passaging, suggesting a modest loss of fitness (Fig. S14C) . Although each of these mutations require a single nucleotide substitution, they are very rare and as of May 2 th 2022 they have been detected cumulatively only in 0.082% and 0.02% of Delta and Omicron genome sequences, respectively (Table S9 and Fig. S15A ). We further tested VSV pseudoviruses (Wu-G614 background) carrying K444E, K444D, K444N and V445D and confirmed that these mutations abrogated S2X324 neutralizing activity ( Fig. S15B and Table S10 ). Importantly, S2X324 retained potent neutralizing activity against V445T, G446V and P499S, as well as against other mutations in the epitope found in known variants such as N439K, N440K and N501Y.

Using Syrian hamsters challenged with SARS-CoV-2, we investigated the in vivo protective efficacy of S2X324 prophylactically and therapeutically. These experiments used S2X324 VH/VL fused to hamster IgG2a constant regions to allow promoting antibody-mediated effector functions in this animal model. Prophylactic administration of S2X324 (blue) or S309 (green) protected hamsters challenged with SARS-CoV-2 Delta in a dose-dependent manner with S2X324 exhibiting an approximately 3-fold higher efficacy than S309 ( Fig. 4A-C) , despite a 20fold difference observed in terms of in vitro potency against SARS-CoV-2 Delta S VSV (Fig. 2B) . These data support the lack of direct correlation between in vitro and in vivo potency as previously reported (44, 45) . Moreover, prophylactic administration of S2X324 hamster IgG2a at 5 mg/kg decreased viral RNA loads in the lungs and trachea of hamsters challenged with BA.2 below detection levels (Fig. 4D) . Therapeutic S2X324 administration (one day after challenge) at 2 and 5 mg/kg reduced lung viral RNA by 2.5 and 3 orders of magnitude compared to the control group, respectively ( Fig. 4E-F) . Viral replication in the lungs was fully abrogated at 5 and 2 mg/kg of S2X324 and reduced by one order of magnitude for animals treated with 0.5 and 0.1 mg/kg of S2X324. No statistically significant differences were observed for animals receiving an Fcsilenced version of S2X324 (N297A, pink), indicating limited contributions of Fc-mediated effector functions in these experimental conditions. (n=6 animals/dose) *, **, ***, **** p< 0.05, p< 0.01, 0.001, and 0.0001 relative to isotype control (MGH2 antibody against circumsporozoite protein of Plasmodium sporozoites), respectively (Mann-Whitney 2-tail T test). D, Quantification of viral RNA load in the lung and trachea of Syrian hamsters 4 days after intranasal infection with SARS-CoV-2 Omicron BA.2 which was preceded 1 day prior by prophylactic intraperitoneal administration of S2X324 hamster IgG2a at 5 mg/kg of body weight. **, ***, **** p< 0.01, 0.001, and 0.0001 relative to control, respectively (Kruskal-Wallis test). E-F, Quantification of replicating virus titers [50% tissue culture infectious dose (TCID50)] (E) and viral RNA load (F) in the lung of Syrian hamsters 4 days after intranasal infection with SARS-CoV-2 Delta followed by therapeutic intraperitoneal administration of S2X324 hamster IgG2a (blue symbols) or N297A mutant IgG2a (purple symbols) at four different doses: 5, 2, 0.5 or 0.1 mg/kg of body weight. *, **, ***, **** p< 0.05, p< 0.01, 0.001, and 0.0001 relative to control, respectively (Mann-Whitney 2-tail T test).

Immunological imprinting, which is also defined as original antigenic sin, was described based on the observation that infections with influenza virus strains similar to that of a prior infection preferentially boost antibody responses against epitopes shared with the original strain (46) . Although this phenomenon is often considered as detrimental, it can also be beneficial, as was the case after the 2009 H1N1 pandemic: initial antibody responses to infection with this newly emerged and antigenically shifted virus were dominated by antibodies targeting the conserved hemagglutinin stem region (47, 48) whereas secondary exposures over the years through vaccination or infection elicited antibody responses to the shifted variant (i.e., to "non-conserved" hemagglutinin epitopes) (47, 49) . Moreover, several studies reported stem-directed antibodymediated protection against H5N1 and H7N9 zoonotic influenza strains through hemagglutinin imprinting during childhood resulting from exposure to seasonal H1N1 and H3N2, respectively (48, 50) . Similarly, we show that exposure to the antigenically shifted Omicron primarily leads to a recall of existing memory B cells specific for epitopes shared by multiple SARS-CoV-2 variants rather than by priming naïve B cells recognizing Omicron-specific epitopes (at least up to 100 days post breakthrough infection), as also recently reported (51) . Although immune imprinting may be beneficial in stimulating responses to cross-reactive SARS-CoV-2 epitopes, antibody responses to some Omicron-specific epitopes were markedly diminished by prior antigenic exposure.

Currently, there is uncertainty regarding the need for vaccines matching dominant circulating SARS-CoV-2 variants (like those used for seasonal influenza) or if the repeated use of Wuhan-Hu-1-based vaccines will suffice. Recent work showed that boosting previously immunized macaques with Beta or Omicron mRNA S vaccines or with Beta RBD nanoparticle vaccines elicited comparably high titers of antibodies broadly neutralizing multiple variants relative to Wuhan-Hu-1-based vaccines (52) (53) (54) . Furthermore, administration of Wuhan-Hu-1based vaccine boosters in humans was shown to elicit appreciable titers of neutralizing antibodies and prevent severe disease associated with Omicron infections (9, 17, 20, (55) (56) (57) . The limited cross-variant neutralization elicited by Omicron primary infection in humans or vaccination of immunologically naïve animals and the data on the specificity of memory B cells presented here indicate that an Omicron-based vaccine might only elicit narrow antibody responses directed towards the vaccine-matched antigen, suggesting that a heterologous prime-boost or a multivalent approach might be preferable (52, (58) (59) (60) (61) (62) (63) (64) (65) . Omicron infection (and presumably Omicron S-based vaccination) of previously immune subjects, however, recalls cross-reactive memory B cells which may further mature overtime to enhance their affinity and neutralizing potency against Omicron, but also to broaden their neutralizing activity against past and future variants. Indeed, multiple studies showed that somatic hypermutations yield RBD-specific mAbs with increased affinity for the homotypic antigen and with augmented resilience to immune evasion of emerging variants (35, (66) (67) (68) (69) .

Understanding antibody responses elicited by and directed towards Omicron sublineages is key to inform public health policies and the design of SARS-CoV-2 and sarbecovirus vaccines (63, 64, (70) (71) (72) . Our data show that Omicron breakthrough infections did not elicit high titers of pan-sarbecovirus neutralizing antibodies (e.g., directed against SARS-CoV), in agreement with recent data (73) . These findings contrast with the observation that pre-existing immunity to SARS-CoV followed by SARS-CoV-2 vaccination was associated with elicitation of pan-sarbecovirus neutralizing antibodies (26) . These different outcomes might be explained by the low frequency of memory B cells encoding for neutralizing antibodies targeting antigenic sites shared between pre-Omicron variants (Wuhan-Hu-1-related strains), Omicron and SARS-CoV, due to the genetic distance between these three antigenically distinct viruses. For instance, Omicron BA.1 and BA.2 harbor variations of the RBD antigenic site II, which is the target of pan-sarbecovirus neutralizing antibodies such as S2X259 (31) and ADG2 (74) , that lead to resistance to neutralization mediated by some of the mAbs recognizing this site (3, 16) . This suggests that conservation of RBD sites across sarbecoviruses may have resulted (at least partially) from limited immune pressure rather than from functional or structural constraints (i.e., some mutations at these conserved sites may remain compatible with viral fitness) (73) .

Finally, recent preclinical assessment of intranasally administered influenza and sarbecovirus vaccine candidates demonstrated the induction of lung-resident protective mucosal humoral and cellular immunity at the site of viral entry (59, 60) (75, 76) . These observations, along with our findings that SARS-CoV-2 breakthrough infections, but not vaccination-only, elicited neutralizing activity in the nasal cavity motivate the development and evaluation of a next generation of vaccines administered intranasally. H.W.V. is a founder and holds shares in PierianDx and Casma Therapeutics. Neither company provided resources. D.C. is currently listed as an inventor on multiple patent applications, which disclose the subject matter described in this manuscript. The Veesler laboratory has received a sponsored research agreement from Vir Biotechnology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Data and Materials Availability. The cryoEM map and coordinates have been deposited to the Electron Microscopy Databank and Protein Data Bank with accession numbers TBD. Materials generated in this study will be made available on request, but may require a completed materials transfer agreement signed with Vir Biotechnology Inc. or the University of Washington. Ribbon diagram of LY-CoV1404/RBD structure (PDB 7MMO, yellow and orange) superimposed onto S2X324/RBD (CryoEM structure, purple and magenta), using the RBD as a reference. The N343 glycan is rendered as blue spheres. Two selected epitope residues and the BA.5 RBD mutation residues relative to BA.1, L452R and F486V, which are positioned outside the S2X324/LY-CoV1404 epitope are indicated with arrows. Counts (#) Table S1 . Neutralizing geometric mean titers (GMTs) against Wu-G614, Delta, BA.1, BA.2, and SARS-CoV S VSV pseudoviruses using plasma from subjects who were infected prior to being vaccinated with 2 doses (n=15) or 3 doses (n=8), subjects who experienced a Delta breakthrough infection with 2 doses (n=15), a BA.1 breakthrough infection with either 2 (n=8) or 3 doses (n=8), or were vaccinated-only with 3 doses (n=7).

Infected Shown is the reciprocal of the half-maximum inhibitory dose (ID50). NC, not calculable. Table S7 . Summary of nucleotide and amino acid mutations found in neutralization-resistant VSV-SARS-CoV-2 G614 S chimera plaques.

Amino acid mutant 

. Vero E6 cells stably expressing the TMPRSS2 protease (VeroE6-TMPRSS2 cells) were generated at Vir (33) . None of the cell lines used was authenticated. Cell lines were routinely tested for mycoplasma contamination.

Blood samples were collected from participants as part of the Hospitalized or Ambulatory Adults with Respiratory Viral Infections (HAARVI) study and was approved by the University of Washington Human Subjects Division Institutional Review Board (STUDY00000959). Baseline socio-demographic and clinical data for these individuals are summarized in Data S1. Samples were obtained from SARS-CoV-2 convalescent and vaccinated individuals under study protocols approved by the local institutional review boards (Canton Ticino Ethics Committee, Switzerland, Comitato Etico Milano Area 1). All donors provided written informed consent for the use of blood and blood derivatives (such as peripheral blood mononuclear cells, sera or plasma) for research.

Participants were enrolled after SARS-CoV-2 positive RT-PCR results that showed S-gene dropout or delay using a primer set that predates the S probe set in the "TaqPath" test kit sold by Thermo Fisher. Specifically, the Delta S 157-158 deletion causes S-gene dropout in our diagnostic RT-qPCR assay. The RT-qPCR assay uses probes for human RNase P and SARS-CoV-2 Orf1b and S gene. S-gene dropout or delay was identified using the following individual sample criteria: 1) internal control RNase P amplification was present, 2) Orf1b amplification was present, and 3) S-gene specific probes showed no amplification or a delay of >5 cycles compared to Orf1b due to the 156-157 deletion in delta. Three samples (278C, 284C, and 286C) included in this analysis were either not sequenced due to low volumes or failed sequencing due to low viral loads, but according to outbreaks.info over 90% of all cases in Washington state at the time were Delta SARS-CoV-2. SARS-CoV-2 genome sequencing was then conducted using a targeted enrichment approach. SARS-CoV-2 was detected using a laboratory-developed test (LDT) or research assay. For the LDT, SARS-CoV-2 detection was performed using real-time RT-PCR with a probe sets targeting Orf1b and S with FAM fluor (Life Technologies 4332079 assays # APGZJKF and #APXGVC4) multiplexed with an RNaseP probe set with VIC or HEX fluor (Life Technologies A30064 or IDT custom) each in duplicate on a QuantStudio 6 instrument (Applied Biosystems). RNA from positive specimens was converted to cDNA using random hexamers and reverse transcriptase (Superscript IV, Thermo) and a sequencing library was constructed using the Illumina TruSeq RNA Library Prep for Enrichment kit (Illumina). The sequencing library was enriched for SARS- 

The SARS-CoV-2 VFLIP ectodomain (77) was produced in Expi293F Cells (ThermoFisher Scientific) grown in suspension using Expi293 Expression Medium (ThermoFisher Scientific) at 37°C in a humidified 8% CO2 incubator with constant rotation at 130 rpm. Cells grown to a density of 3 million cells per mL were transfected using the ExpiFectamine 293 Transfection Kit (ThermoFisher Scientific) and cultivated for four days prior to supernatent harvest. SARS-CoV-2 VFLIP was purified from clarified supernatants using a HisTrapHP column (Cytiva) and washed with 10 column volumes of 25 mM sodium phosphate pH 8.0 and 150 mM NaCl before elution on a gradient up to 500 mM imidazole. Purified protein was buffer exchanged into 20 mM Tris-HCl pH 8.0 and 100 mM NaCl, concentrated using 100 kDa MWCO centrifugal filters (Amicon Ultra) to 1-2 mg/mL, and flash frozen.

Replicate cultures of total unfractionated PBMC from SARS-CoV-2 infected or vaccinated individuals were seeded in 96 U-bottom plates (Corning) in RPMI1640 supplemented with 10% Hyclone, sodium pyruvate, MEM non-essential amino acid, stable glutamine and Penicillin-Streptomycin. Memory B cell stimulation and differentiation was induced by adding 2.5 μg/ml R848 (3 M) and 1000 U/ ml human recombinant IL-2 at 37 °C and 5% CO2. After 10 days, the cell culture supernatants were collected for further analysis by ELISA.

Plasma cells from peripheral blood were stained with PE-conjugated anti-CD138 (BD-Pharmingen), enriched by magnetic separation with anti-PE microbeads (Miltenyi) and finally purified by cell sorting on Sony cell sorter. Cells were seeded at 0.5 cells/well in multiple 384 well plates in 50 μl complete RPMI 1640 medium supplemented with 10% FCS (Hyclone) and 10 ng/ml human r-IL6 (R&D). After three days 20 μl of culture supernatants were collected using an automated liquid handling equipment (Perkin Elmer) and tested in parallel micro-ELISA (5 μl per test) for the presence of IgG antibodies against different SARS-CoV-2 RBDs and PBS as negative control.

Generation of VSV pseudovirus. Replication defective VSV pseudovirus expressing SARS-CoV-2 spike proteins corresponding to the ancestral Wuhan-Hu-1 virus and the VOCs were generated as previously described (3) . IC50 values were calculated from the interpolated value from the log(inhibitor) versus response, using variable slope (four parameters) nonlinear regression with an upper constraint of ≤100, and a lower constrain equal to 0. Each neutralization experiment was conducted on two independent experiments -that is, biological replicates -in which each biological replicate contains a technical duplicate or triplicate. IC50 values across biological replicates are presented as geometric mean ± s.d. For sotrovimab, IC50 values were calculated as described above using an upper constraint of <100. For pseudoviruses expressing spike substitutions that resulted in decreased infectivity using Vero E6 cells, Vero E6-TMPRSS2 cells were substituted as target cells for neutralization assays.

Ninety-six half area well-plates (Corning, 3690) were coated overnight at 4 °C with 25 μl of sarbecovirus RBD proteins of SARS-CoV-2 (YP_009724390.1), RaTG13 (QHR63300.2), Pangolin_Guangdong-2019 (EPI_ISL_410721), Pangolin_Guangxi, SARS-CoV Urbani (AAP13441.1) and WIV1 (AGZ48831.1), prepared at 5 μg ml−1 in PBS pH 7.2. Plates were then blocked with PBS 1% BSA (Sigma-Aldrich, A3059) and subsequently incubated with mAb serial dilutions for 1 h at room temperature. After 4 washing steps with PBS 0.05% Tween 20 (PBS-T) (Sigma-Aldrich, 93773), goat anti-human IgG secondary antibody (Southern Biotech, 2040-04) was added and incubated for 1 h at room temperature. Plates were then washed four times with PBS-T and 4-nitrophenyl phosphate (pNPP, Sigma-Aldrich, 71768) substrate was added. After 30 min incubation, absorbance at 405 nm was measured by a plate reader (Biotek) and data were plotted using Prism GraphPad 9.1.0.

For anti-S ELISA, 50 μL of 2 μg/mL S was plated onto 384-well Nunc Maxisorp (ThermoFisher) plates in PBS and sealed overnight at room temperature. The next day plates were washed 4 × in Tris Buffered Saline Tween (TBST-20mM Tris pH 8, 150mM NaCl, 0.1% Tween) using a plate washer (BioTek) and blocked with Casein (ThermoFisher) for 1 h at 37°C. Plates were washed 4 × in TBST and 1:5 serial dilutions of nasal swab in universal transport media were made in 50 μL TBST and incubated at 37°C for 1 h. Plates were washed 4 × in TBST, then anti-human (Invitrogen) horseradish peroxidase-conjugated antibodies were diluted 1:5,000 and 50 μL added to each well and incubated at 37°C for 1 h. Plates were washed 4 × in TBST and 50 μL of TMB (SeraCare) was added to every well for 3 min at room temperature. The reaction was quenched with the addition of 50 μL of 1 N HCl. Plates were immediately read at 450 nm on a VarioSkanLux plate reader (ThermoFisher) and data plotted and fit in Prism (GraphPad) using nonlinear regression sigmoidal, 4PL, X is log(concentration) to determine EC50 values from curve fits. Where the curve did not reach an OD450 of 4, a constraint of OD450 4 was placed on the upper bounds of the fit.

Recombinant protein production for SPR binding assays SARS-CoV-2 RBD constructs contain residues 328-531 of the spike protein from GenBank NC_045512.2 with an N-terminal signal peptide and a C-terminal thrombin cleavage site-Twin-Strep-8×His-tag. For SPR binding assays, proteins were expressed in Expi293F cells (Thermo Fisher Scientific) at 37 °C and 8% CO2. Transfections were performed using the ExpiFectamine 293 Transfection Kit (Thermo Fisher Scientific). Cell culture supernatants were collected three to five days after transfection and supplemented with 10x PBS to a final concentration of 2.5x PBS (342.5 mM NaCl, 6.75 mM KCl and 29.75 mM phosphates). SARS-CoV-2 RBDs were purified using a Cobalt affinity column (HisTALON Superflow column from Takara or HiTrap TALON crude column from Cytiva) followed by buffer exchange into PBS using a HiPrep 26/10 desalting column (Cytiva) or, for the Omicron BA.1 and BA.2 RBDs, a Superdex 200 Increase 10/300 GL column (Cytiva).

Measurements were performed using a Biacore T200 instrument. A CM5 chip with covalently immobilized StrepTactin XT was used for surface capture of Twin-Strep Tag containing RBDs. Running buffer was HBS-EP+ pH 7.4 (Cytiva) and measurements were performed at 25 C. Experiments were performed with a 3-fold dilution series of monomeric S2X324 Fab: 300, 100, 33, 11 nM and were run as single-cycle kinetics. Data were double reference-subtracted and fit to a binding model using Biacore Evaluation software. The 1:1 binding model was used to estimate the kinetics parameters. The experiment was performed twice with two biological replicates for each ligand (RBDs). KD values were reported as the average of two replicates with the corresponding standard deviation.

Biolayer interferometry was used to assess S2X324 competition with S2K146 and S309 using an Octet HTX (Sartorius). All reagents were prepared in kinetics buffer (PBS 0.01% BSA) at the indicated concentrations. His-tagged SARS-CoV-2 RBD was prepared at 8 μg ml−1 and loaded on prehydrated anti-penta-HIS biosensors (Sartorius) for 3 min. Biosensors were then moved into a solution containing S2X324 mAb (20 μg ml−1) and association recorded for 7 min. A second association step was subsequently performed into S2X324 (as control), S2K146 and S309 mAbs solutions at 20 μg ml−1 and recorded for 7 min. Response values were exported and plotted using GraphPad Prism 9.1.0.

SARS-CoV-2 mouse/rabbit Fc-tagged RBDs (final concentration 20 ng/ml) were incubated with serially diluted recombinant mAbs (from 25 µg/ml) and incubated for 1 h 37°C. The complex RBD:mAbs was then added to a pre-coated hACE2 (2 µg/ml in PBS) 96-well plate MaxiSorp (Nunc) and incubated 1 hour at room temperature. Subsequently, the plates were washed, and a goat anti-mouse/rabbit IgG (Southern Biotech) coupled to alkaline phosphatase (Jackson Immunoresearch) added to detect mouse Fc-tagged RBDs binding. After further washing, the substrate (p-NPP, Sigma) was added, and plates read at 405 nm using a microplate reader (Biotek). The percentage of inhibition was calculated as follow: (1-((OD sample-OD neg ctr)/(OD pos. ctr-OD neg. ctr))*100

Cell-surface mAb-mediated S1 shedding CHO cells stably expressing the prototypic SARS-CoV-2 S were harvested, washed in wash buffer (PBS 1% BSA 2 mM EDTA) and resuspended in PBS. Cells were then counted and 90'000 cells/well were dispensed into a round-bottom 96 well plate (Corning) to be treated with 10 ug/ml TPCK-Trypsin (Worthington Biochem) for 30 min at 37°C. After a washing step, cells were incubated with 15 µg/ml mAbs solution for 180, 120, 60, 30 or 5 min at 37°C. After the incubation for the allotted time, cells were washed with ice-cold wash buffer and stained with 1.5 µg/ml Alexa Fluor647-labeled Goat Anti-Human IgG secondary Ab (Jackson Immunoresearch) for 30 min on ice in the dark. Cells were then washed twice with cold wash buffer and analyzed using a ZE5 cytometer (Biorad) with acquisition chamber T= 4°C. Binding at each time point (MFI) was determined normalizing to the MFI at 5 minutes time point and data plotted using GraphPad Prism v. 9.1.1

Recombinantly expressed and purified S2X324 Fab and SARS-CoV-2 Omicron BA.1 S (16) were incubated at 1 mg/ml (for UltraAuFoil grids) or 0.1mg/ml (for lacey thin carbon grids) with a 1.2 molar excess of S2X324 Fab at 4°C for 1 hr. Three microliters of the complex mixture were loaded onto freshly glow discharged R 2/2 UltrAuFoil grids (200 mesh) or lacey grids covered with a thin layer of home-made carbon, prior to plunge freezing using a Vitrobot MarkIV (ThermoFisher Scientific) with a blot force of 0 and 6 sec blot time (for the UltrAuFoil grids) or with a blot force of -1 and 3 sec blot time (for the lacey thin carbon grids) at 100 % humidity and 22°C. Data were acquired using an FEI Titan Krios transmission electron microscope operated at 300 kV and equipped with a Gatan K3 direct detector and Gatan Quantum GIF energy filter, operated in zero-loss mode with a slit width of 20 eV. Automated data collection was carried out using Leginon (78) at a nominal magnification of 105,000x with a pixel size of 0.843 Å. The dose rate was adjusted to 15 counts/pixel/s, and each movie was acquired in super-resolution mode fractionated in 75 frames of 40 ms. 10,842 micrographs were collected with a defocus range comprised between -0.5 and -2.5 μm. Movie frame alignment, estimation of the microscope contrast-transfer function parameters, particle picking, and extraction were carried out using Warp (79) . Two rounds of reference-free 2D classification were performed using CryoSPARC (80) to select well-defined particle images. These selected particles were subjected to two rounds of 3D classification with 50 iterations each (angular sampling 7.5˚ for 25 iterations and 1.8˚ with local search for 25 iterations), using our previously reported closed SARS-CoV-2 S structure as initial model (PDB 6VXX) (81) using Relion (82) . 3D refinements were carried out using non-uniform refinement along with per-particle defocus refinement in CryoSPARC (83). Selected particle images were subjected to the Bayesian polishing procedure (84) implemented in Relion3.0 before performing another round of non-uniform refinement in CryoSPARC followed by per-particle defocus refinement and again non-uniform refinement. To improve the density of the S/S2X324 interface, the particles from the non-uniform refinement were subjected to focus 3D classification without refining angles and shifts using a soft mask on the closed RBD and bound S2X324 variable domains with a tau value of 60 in Relion. Particles belonging to classes with the best resolved local density were selected and subject to local refinement using CryoSPARC. Local resolution estimation, filtering, and sharpening were carried out using CryoSPARC. Reported resolutions are based on the gold-standard Fourier shell correlation (FSC) of 0.143 criterion and Fourier shell correlation curves were corrected for the effects of soft masking by high-resolution noise substitution (85, 86) .

UCSF Chimera (87) and Coot (88) were used to fit atomic models into the cryoEM maps. The Omicron BA.1 S/S2X324 and RBD/S2X324 models were refined and relaxed using Rosetta using sharpened and unsharpened maps (89, 90) .

A VSV-SARS-CoV-2 Wuhan-Hu-1 D614G S and Omicron BA.1 S chimera were used to select for mAb resistant mutants, as previously described (35) . Briefly, mutants were recovered by plaque isolation on Vero E6 cells with the indicated mAb in the overlay. 

Animal experiments were carried out by two independent laboratories. For the results shown in Fig.4 (A-C), 64 male golden Syrian hamsters (Mesocricetus auratus; RjHan:AURA) of 5-6 weeks of age (average weight 60-80 grams) were purchased from Janvier Laboratories (Le Genest-Saint-Isle, France) and handled under specific pathogen-free conditions. The animals were housed and manipulated in isolators in a Biosafety level-3 facility, with ad libitum access to water and food. Before manipulation, animals underwent an acclimation period of one week. (91) . Briefly, the animals were anesthetized with an intraperitoneal injection of 200 mg/kg ketamine (Imalgène 1000, Merial) and 10 mg/kg xylazine (Rompun, Bayer), and 100 µL of physiological solution containing 6x10 4 PFU of SARS-CoV-2/VoC delta (GISAID ID : EPI_ISL_2029113, supplied by Dr Olivier Schwartz, Institut Pasteur, Paris, France) was then administered intranasally to each animal (50 µL/nostril). Mockinfected animals received the physiological solution only. Infected and mock-infected hamsters were housed in separated isolators and were followed-up daily, for four days, when the body weight and the clinical score were noted. At day 4 post-inoculation, the animals were euthanized with an excess of anesthetics (ketamine and xylazine) and exsanguination. Blood samples were collected by cardiac puncture; after coagulation, the tubes were centrifuged at 2,000 x g during 10 min at 4°C, the serum was collected and frozen at -80°C until further analyses. The lungs were collected, weighted and frozen at -80°C until further analyses. For the results shown in Fig.4 (D-E) , the hamster infection model of SARS-CoV-2 including the associated analytical procedures, have been described before (92, 93) . Briefly, female Syrian hamsters (Mesocricetus auratus) of 6-8 weeks old were anesthetized with ketamine/xylazine/atropine and inoculated intranasally with 50 μL containing 1×10 4 TCID50 Delta (B.1.617.2; EPI_ISL_2425097) or BA.2 (94) . Animals were treated once by intraperitoneal injection 24h before or after SARS-CoV-2 challenge (i.e., prophylactic vs therapeutic administration) with hamsterized S2X324 mAb. Hamsters were monitored for appearance, behavior and weight. At day 4 pi, hamsters were euthanized by i.p. injection of 500 μL Dolethal (200mg/ml sodium pentobarbital, Vétoquinol SA). Lungs were collected for viral RNA and infectious virus quantification by RT-qPCR and end-point virus titration, respectively. Serum samples were collected at day 4 pi for analysis of Ab levels. Animals with circulating Ab levels below the detection limit, indicating misdosing, were excluded.

For data shown in Fig.4C , frozen lungs fragments were weighted and homogenized with 1 mL of ice-cold DMEM (31966021, Gibco) supplemented with 1% penicillin/streptomycin (15140148, Thermo Fisher) in Lysing Matrix M 2 mL tubes (116923050-CF, MP Biomedicals) using the FastPrep-24™ system (MP Biomedicals), and the following scheme: homogenization at 4.0 m/s during 20 sec, incubation at 4°C during 2 min, and new homogenization at 4.0 m/s during 20 sec. The tubes were centrifuged at 10.000 x g during 1 min at 4°C. Afterwards, 125 µL of the tissue homogenate supernatant were mixed with 375 µL of Trizol LS (10296028, Invitrogen) and the total RNA was extracted using the Direct-zol RNA MiniPrep Kit (R2052, Zymo Research). The presence of SARS-CoV-2 RNA in these samples was evaluated by one-step RT-qPCR in a final volume of 12.5 μL per reaction in 384-wells PCR plates using a thermocycler (QuantStudio 6 Flex, Applied Biosystems). Briefly, 2.5 μL of RNA were added to 10 μL of a master mix containing 6.25 μL of 2X reaction mix, 0.2 µL of MgSO4 (50 mM), 0.5 µL of Superscript III RT/Platinum Taq Mix (2 UI/µL) and 3.05 μL of nuclease-free water containing the nCoV_IP2 primers (nCoV_IP2-12669Fw: 5'-ATGAGCTTAGTCCTGTTG-3'; nCoV_IP2-12759Rv: 5'-CTCCCTTTGTTGTGTTGT-3') at a final concentration of 400 nM, and the nCoV_IP2 probe (5'-FAM-AGATGTCTTGTGCTGCCGGTA-3'-TAMRA) at a final concentration of 200 nM (95) .The amplification conditions were as follows: 55°C for 20 min, 95°C for 3 min, 50 cycles of 95°C for 15 s and 58°C for 30 s, and a last step of 40°C for 30 s. Viral load quantification (expressed as RNA copy number/g of tissue) was assessed by linear regression using a standard curve of six known quantities of RNA transcripts containing the RdRp sequence (ranging from 10 7 to 10 2 copies). For data shown in Fig. 4 D, E, hamster lung and trachea tissues were collected after sacrifice and were homogenized using bead disruption (Precellys) in 350 µL TRK lysis buffer (E.Z.N.A.® Total RNA Kit, Omega Bio-tek) and centrifuged (10.000 rpm, 5 min) to pellet the cell debris. RNA was extracted according to the manufacturer's instructions. RT-qPCR was performed on a LightCycler96 platform (Roche) using the iTaq Universal Probes One-Step RT-qPCR kit (BioRad) with N2 primers and probes targeting the nucleocapsid (92) . Standards of SARS-CoV-2 cDNA (IDT) were used to express viral genome copies per mg tissue.

Lung tissues were homogenized using bead disruption (Precellys) in 350 µL minimal essential medium and centrifuged (10,000 rpm, 5min, 4°C) to pellet the cell debris. To quantify infectious SARS-CoV-2 particles, endpoint titrations were performed on confluent Vero E6 cells in 96-well plates. Viral titers were calculated by the Reed and Muench method (96) using the Lindenbach calculator and were expressed as 50% tissue culture infectious dose (TCID50) per mg tissue.

Structures of the Wuhan-Hu-1 and BA.1 RBDs were prepared as previously described (97, 98) . The coordinates of the Wuhan-Hu-1 RBD were obtained from PDB 6M0J (42) for which ACE2 was removed and as previously described (25) the glycan at position 343 added in the RBD using ISOLDE (99) to visually place, link and minimize each monosaccharide beyond the Nacetylglucosamine for which there was density. The resulting model was then prepared using QuickPrep (MOE v2020.0901, https://www.chemcomp.com). The coordinates of the BA.1 RBD were obtained from PDB 7TN0 (16) with the complex glycan at position 343 added before refinement using ISOLDE and model preparation using QuickPrep. The coordinates of the BA.2 RBD were generated by mutating positions 371, 376, 405, and 408 of the refined BA.1 structure, optimizing the rotamers at the four positions using Repack in Protein Builder (MOE v2020.0901), followed by model preparation using QuickPrep.

The 3 RBD structures were each parameterized using tleap with the Amber ff14SB force field (100) for the protein, GLYCAM_06j-1 for the glycan (101), TIP3P for water (truncated octahedral cell with 18 Å buffer around solute) (102); the Joung & Cheatham parameters (103) were used for the ions neutralizing the charged solute (2 Cl-ions for Wuhan-Hu-1, 6 Cl-ions for BA.1 and BA.2) and the additional 0.15 M excess Na+ and Cl-ions (80 Na+ and 80 Cl-for Wuhan-Hu-1, 76 of each for BA.1 and BA.2). We generated 4.8 μs of aggregate MD for each of the three RBDs by performing eight independent MD simulations seeded with different initial velocities. Each of these 24 simulations was subjected to a nine-stage minimization and equilibration procedure as previously described (97) . This involved 10,000 steps of restrained minimization with a 100 kcal/mol Å 2 force constant applied to all heavy atoms resolved in the structure followed by 100 ps of restrained MD heating to 300 K, 100 ps of restrained MD at 300 K, 250 ps of restrained MD with a 10-fold reduction in restraint force constant at 300 K, 10,000 steps of backbone-restrained minimization, 100 ps of backbonerestrained MD, 100 ps of backbone-restrained MD at 300 K, 100 ps of backbone-restrained MD with a further 10-fold reduction in restraint force constant, 100 ps of backbone-restrained MD with another 10-fold reduction in restraint force constant (0.1 kcal/mol Å 2 ), and 2.5 ns of unrestrained MD at 300 K. An additional 0.6 μs of unrestrained MD simulation was performed for each of the 24 independent simulations. Simulations were processed using cpptraj (104) to image the coordinates, RMS-align RBD C⍺ atoms to the S309:RBD complex (PDB ID: 7TN0), and to strip solvent and ions. Volumetric density maps were computed using cpptraj with grid points spaced 0.25 Å over a grid with dimensions 279 Å, 296 Å, 307 Å. This resulted in Cartesian coordinates of grid points and the probability of finding any glycan atom at those grid points. This procedure was repeated for S309 from the S309:RBD complex used to align RBDs above. The maximum probability (isovalue) at which no glycan atom from RBD Wuhan-Hu-1 occupied a grid point also occupied by S309 was 0.057 and this isovalue was used for subsequent analysis with BA.1 and BA.2. Overlap was calculated by counting the grid points occupied by S309 (probabilities were one or zero because it was a static structure) and any glycan atom if the probability for the glycan was 0.057 or less at that grid point. Smaller isovalues increase the volume size because ephemeral glycan conformations are included in the map whereas a larger isovalue (occupancy probability) reduces the volume size because only persistent glycan conformations are included in the map. The total volume housed by a volumetric density map for a glycan was computed by counting the grid points occupied by the glycan with an isovalue of 0.057. Renderings for volumetric density maps of the glycan were generated using VMD (105) .

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

Comparable neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. medRxiv (2022)

Emergence of Omicron third lineage BA.3 and its importance

Continued emergence and evolution of Omicron in South Africa: New BA.4 and BA.5 lineages. bioRxiv (2022)

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

The Omicron variant is highly resistant against antibodymediated neutralization -implications for control of the COVID-19 pandemic

Balazs, mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Delineating antibody escape from Omicron variants. bioRxiv (2022)

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

SARS-CoV-2 spike conformation determines plasma neutralizing activity

McGuire, mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses

Characterization of immune responses in fully vaccinated individuals following breakthrough infection with the SARS-CoV-2 delta variant

Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection

1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Hybrid immunity

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

Clonal dissection of the human memory B-cell repertoire following infection and vaccination

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Broad sarbecovirus neutralization by a human monoclonal antibody

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv (2021)

A glycan gate controls opening of the SARS-CoV-2 spike protein

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. bioRxivorg (2022)

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. bioRxiv (2022)

On the doctrine of original antigenic sin

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

Identification and structure of a multidonor class of head-directed influenza-neutralizing antibodies reveal the mechanism for its recurrent elicitation

Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting

Omicron breakthrough infection drives crossvariant neutralization and memory B cell formation. bioRxiv (2022)

Seder, mRNA-1273 or mRNA-Omicron

Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination

CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated

Neutralization profile after recovery from SARS-CoV-2 omicron infection

Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants. bioRxiv (2022)

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals

Puchhammer-St&#x00F6, Human primary Omicron BA.1 and BA.2 infections result in sub-lineage-specific neutralization

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine. Research Square (2022)

Evolution of antibody immunity to SARS-CoV-2

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models. bioRxivorg (2022)

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

Differential escape of neutralizing antibodies by SARS-CoV-2 Omicron and preemergent sarbecoviruses

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity

Automated molecular microscopy: the new Leginon system

Real-time cryo-electron microscopy data preprocessing with Warp

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

New tools for automated high-resolution cryo-EM structure determination in RELION-3

Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction

A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis

High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy

Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy

UCSF Chimera--a visualization system for exploratory research and analysis

Features and development of Coot

Automatically Fixing Errors in Glycoprotein Structures with Rosetta

Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta

COVID-19-associated olfactory dysfunction reveals SARS-CoV-2 neuroinvasion and persistence in the olfactory system. bioRxiv (2020)

STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12

Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

ISOLDE: a physically realistic environment for model building into lowresolution electron-density maps

Ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB

GLYCAM06: a generalizable biomolecular force field. Carbohydrates

Comparison of simple potential functions for simulating liquid water

Cheatham 3rd, Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations

Cheatham 3rd, Parallelization of CPPTRAJ enables large scale analysis of molecular dynamics trajectory data

VMD: visual molecular dynamics